Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Qizhu Yuling Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Esophagus Cancer：A Randomized, Double-blind, Controlled and Multi-center Clinical Study

NCT05626309 is registered in ClinicalTrials.gov with Jie Li as lead sponsor.

NCT NCT05626309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05626309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Qizhu Yuling Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Esophagus Cancer：A Randomized, Double-blind, Controlled and Multi-center Clinical Study
Lead sponsor
Jie Li
Phase
Not applicable
Overall status
Unknown status
Start date
October 1, 2022
Completion date
November 30, 2024
Enrollment
310 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

esophagus cancer